OEFA - ETF AI Analysis
Top Page
O'Shares International Developed Quality Dividend ETF (OEFA)
OEFA, the O'Shares International Developed Quality Dividend ETF, earns a solid overall rating thanks to several high-quality, financially strong holdings like Novartis and AstraZeneca, which bring robust profitability, positive earnings sentiment, and reliable dividends to the portfolio. Industrial and tech names such as SAP and Schneider Electric contribute good fundamentals but face bearish technical trends and relatively expensive valuations, which slightly weigh on the fund’s rating. A key risk factor is the ETF’s reliance on a number of stocks that appear overvalued or overbought, which could lead to short-term corrections even though the underlying businesses are strong.
OEFA vs. SPDR S&P 500 ETF (SPY)
- AUM
- 34.73M
- Region
- Developed Markets
- Expense Ratio
- 0.48%
- Beta
- 0.65
- Issuer
- ALPS
- Inception Date
- Aug 19, 2015
- Dividend Yield
- 1.60%
- Asset Class
- Equity
- Index Tracked
- O'Shares International Developed Quality Dividend Index - Benchmark TR Net
OEFA Summary
O'Shares International Developed Quality Dividend ETF (OEFA) is an ETF that follows the O'Shares International Developed Quality Dividend Index, focusing on established companies in developed countries that pay steady dividends. It holds large, well-known names like ASML Holding and Novartis, spread across sectors such as healthcare, industrials, and consumer companies, giving investors international diversification and potential income from dividends. Someone might invest in OEFA to add global, dividend-paying stocks to their portfolio without picking individual shares. A key risk is that the value of the ETF can go up and down with global stock markets.
How much will it cost me?
This ETF has an expense ratio of 0.48%, which means you’ll pay about $4.80 per year for every $1,000 you invest. That’s higher than the average low-cost index ETF because this fund is more specialized and rules-based, focusing on quality, dividend-paying international stocks rather than simply tracking a broad market index.
What would affect this ETF?
This ETF focuses on developed markets outside the U.S., with big positions in health care, consumer companies, and major European and Canadian names like Novartis, AstraZeneca, Royal Bank of Canada, and ASML, so it can benefit if global growth is steady, interest rates fall or stabilize, and demand for reliable dividend payers stays strong. On the other hand, it could be hurt by slower economic growth in Europe and other developed regions, rising interest rates that make dividends less attractive, currency swings versus the U.S. dollar, or new regulations affecting banks, drugmakers, and other large companies in its portfolio.
OEFA Top 10 Holdings
This ETF leans heavily on non-U.S. developed markets, with Europe doing most of the heavy lifting and Japan adding a growth twist. ASML has been a powerful long-term engine but is catching its breath lately, while SAP’s strong recent run gives the fund a tech-flavored boost despite its modest weight. On the defensive side, healthcare names like Novartis and Roche are steadily supporting performance, even as AstraZeneca loses a bit of steam. Consumer giant FAST RETAILING adds some punch, though its rich valuation could cap further upside.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 4.28% | $1.48M | EUR 539.67B | 50.70% | 76Outperform |
 CH:NOVN | Novartis AG | 3.24% | $1.13M | CHF 244.89B | 35.30% | 80Outperform |
 DE:SAP | SAP SE | 3.14% | $1.09M | EUR 246.65B | -6.46% | 66Neutral |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 RY | Royal Bank Of Canada | ― | ― | ― | ― | 75Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 ES:IBE | Iberdrola | 2.66% | $922.20K | EUR 146.27B | 26.31% | 67Neutral |
 FR:OR | L'Oreal | 2.52% | $875.26K | EUR 232.44B | 18.95% | 71Outperform |
 GB:REL | RELX plc | 2.46% | $854.71K | GBP 51.93B | -11.32% | 76Outperform |
 JP:9983 | FAST RETAILING CO | 2.41% | $837.78K | JPY 23.68T | 38.24% | 74Outperform |
OEFA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For OEFA, the sentiment is Positive. The current price of 35.71 is above the 20-day moving average (MA) of 35.17, above the 50-day MA of 35.25, and above the 200-day MA of 34.11, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 58.62 is Neutral, neither overbought nor oversold. The STOCH value of 49.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OEFA.
OEFA Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| OEFA | $35.71 | $38.00(6.41% Upside) | $34.73M | 0.48% | 70Outperform |
 INEQ | $39.03 | $46.69(19.64% Upside) | $92.71M | 0.45% | 66Neutral |
 DMXU | $37.06 | $46.35(25.07% Upside) | $60.41M | 0.03% | 61Neutral |
 DEEF | $39.44 | $45.46(15.26% Upside) | $55.41M | 0.24% | 59Neutral |
 QLVD | $34.71 | $38.36(10.52% Upside) | $53.68M | 0.12% | 68Neutral |
 RWIN | $27.29 | $32.46(18.95% Upside) | $20.39M | 0.42% | 66Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| OEFA | O'Shares International Developed Quality Dividend ETF | 35.71 | 3.14 | 9.65% | |
| INEQ | Columbia International Equity Income Etf | 39.03 | 4.88 | 14.29% | |
| DMXU | Xtrackers Bloomberg Developed Markets ex US Equity ETF | 37.05 | 3.35 | 9.94% | |
| DEEF | Xtrackers FTSE Developed ex US Multifactor ETF | 39.44 | 5.62 | 16.61% | |
| QLVD | FlexShares Developed Markets ex-US Quality Low Volatility Index Fund | 34.71 | 4.90 | 16.42% | |
| RWIN | Rayliant NxtGen Multifactor International Equity ETF | 27.29 | 1.57 | 6.08% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.